Belite Bio Raises $350 Million in Public Offering to Advance Stargardt Disease Treatment
Key Insights
Belite Bio (search) completed a $350 million follow-on public offering of American Depositary Shares, with potential to reach $402.5 million if underwriters exercise their over-allotment option.
The clinical-stage company focuses on developing novel therapeutics for retinal degenerative eye diseases including Stargardt disease (search) and Geographic Atrophy (search) in advanced dry age-related macular degeneration (search).
Belite Bio (search) has completed its phase 3 clinical trial for drug candidate Tinlarebant for Stargardt disease (search) and plans to file a new drug application with the FDA in the first half of 2026.
Belite Bio (search), Inc (NASDAQ: BLTE) successfully completed a substantial $350 million follow-on offering of American Depositary Shares, marking a significant funding milestone for the clinical-stage biotechnology company focused on retinal degenerative diseases. The offering closed on December 3, 2025, with potential gross proceeds reaching $402.5 million if underwriters exercise their over-allotment option in full.
Strong Institutional Support
The offering was led by a consortium of prominent investment banks, with Morgan Stanley (search) & Co. LLC, Leerink Partners (search), BofA Securities (search) and Cantor serving as joint active book-running managers. H.C. Wainwright & Co. acted as lead manager, while Maxim Group LLC and Titan Partners Group, a division of American Capital Partners, served as co-managers for the offering.
Focus on Unmet Medical Needs
Based in San Diego, Belite Bio (search) is developing novel therapeutics targeting retinal degenerative eye diseases with significant unmet medical needs. The company's primary focus areas include Stargardt disease (search) and Geographic Atrophy (search) in advanced dry age-related macular degeneration (search), in addition to specific metabolic diseases.
Advanced Clinical Development
The company has achieved a critical regulatory milestone by completing its phase 3 clinical trial for Tinlarebant, its lead drug candidate for Stargardt disease (search). This achievement positions Belite Bio (search) to file a new drug application with the U.S. FDA in the first half of 2026, representing a potential near-term catalyst for the company.
Strategic Positioning
The substantial funding provides Belite Bio (search) with significant financial resources to advance its pipeline and support its regulatory filing strategy. The successful completion of this large-scale public offering demonstrates strong investor confidence in the company's approach to addressing serious retinal degenerative conditions that currently lack effective treatment options.
The timing of this funding round, following the completion of phase 3 trials for Tinlarebant, positions the company to execute on its regulatory strategy and potentially bring a novel treatment option to patients with Stargardt disease (search), a rare inherited retinal dystrophy that causes progressive vision loss.